CA-THE-MOPRIA-ALLIANCE
10.9.2020 10:02:10 CEST | Business Wire | Press release
The Mopria® Alliance , a global non-profit organization providing universal standards and solutions for print and scan, today announced Android 11 includes new print capabilities and enhancements contributed by the Alliance in collaboration with the Google Android team.
A new “Share-to-Print” feature of the Android Default Print Service enables users to print images and documents from thousands of social media and productivity applications directly from their Android device. Practically any Android app that allows users to share files such as JPEG, BMP, PNG, GIF and PDF, now also includes a convenient and simple option to print those items as well.
Additionally, the “Share-to-Print” path for photo printing supports specific enhancements to ensure best fit and higher resolution on the printed page. These enhancements result in high-quality prints, regardless of aspect ratio of the photo or size of the print.
“With this update, we set out to integrate print features that would make the lives of mobile users easier and continue to push the envelope of what we can provide in the Default Print Service,” said Ingrid Kelly, Chairperson of the Board at the Mopria Alliance. “We achieved those goals in the Android 11 update, and we are excited to continue to invest in and demonstrate our commitment to providing an enhanced printing experience for Android users.”
For people wanting to maximize the features available in their printers that may not be supported by the Default Print Service, the update adds on-the-fly selection of other brand-specific print services and the Mopria Print Service . Users are able to select and install these additional print services directly in their print workflow to enable even more print features.
To date, Mopria print technology has been installed on more than 2 billion devices, including Windows PCs and laptops, Android phones and tablets, FireOS tablets and ChromeOS notebooks. Mopria print technology is designed to simplify desktop printing and mobile printing to more than 4,000 printer models and more than 120 million Mopria certified printers .
The Mopria Alliance membership represents many of today’s global printer businesses, OS providers, device manufacturers and software vendors. In addition to the founding companies, Canon, HP, Samsung and Xerox, Mopria Alliance members include Adobe, Brother, EFI, Epson, Fuji Xerox, Huawei, Konica Minolta, Kyocera, Lexmark, Microsoft, OKI Data, Pantum, Primax, Qualcomm, Ricoh, Toshiba, Xiaomi and YSoft.
The new Default Print Service features will be available to Android users who update to Android version 11. For the latest list of Mopria certified printers and print accessories, please visit https://mopria.org/certified-products .
About the Mopria® Alliance
The Mopria® Alliance is a non-profit membership organization of leading global technology companies with the mission of providing universal standards and solutions for print and scan. With a focus on mobility and modern productivity trends, Mopria technology is used to allow users to interact intuitively and seamlessly with a printer, multi-function printer or scanner, regardless of brand. Learn more at www.mopria.org . Print. Scan. Go.
Android is a trademark of Google Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200910005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom